Do you consider discontinuing brentuximab in stage III-IV classical Hodgkin lymphoma patients on AVD+brentuximab who have a good response to 2 cycles?

Now that the 4 year progression free survival results are available (Bartlett, 2019 ASH abstracts, #4026: 4-y PFS A-AVD 82%, ABVD 75%), the evidence for superiority of A-AVD is clear. This better outcome with A-AVD was achieved when the brentuximab was kept included through all 6 cycles of chemother...